Full-Time

Manager Practice Development Education

Posted on 9/11/2026

Deadline 9/21/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$117k - $201.3k/yr

Remote in USA + 1 more

More locations: Irvine, CA, USA

Hybrid

Remote within the US, with approximately 60% travel throughout the United States and Canada.

Bachelor's

Category
Customer Experience & Support (1)
Required Skills
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A minimum of a bachelor's degree is required.
  • A minimum of 6+ years of experience in ophthalmology, optometry, eye care, medical devices, or a related healthcare environment is required.
  • Deep knowledge of ophthalmic diagnostics, biometry, patient flow, refractive cataract surgery, and practice operations is required.
  • Demonstrated ability to develop and deliver educational programs for healthcare professionals is required.
  • Strong communication, facilitation, presentation, and relationship-building skills are required.
  • Proven ability to collaborate effectively across functions and influence stakeholders without direct authority is required.
  • Experience working in virtual, live, and hybrid educational environments is required.
  • Ability to travel approximately 60% throughout the United States and Canada is required.
Responsibilities
  • Help lead the development and execution of practice development programs designed to improve business performance, premium conversion, patient engagement, and overall practice effectiveness across ophthalmology and optometry accounts.
  • Partner with commercial and corporate account teams to identify customer opportunities and deliver strategic solutions aligned to customer and business objectives.
  • Serve as a subject matter expert on practice optimization, patient flow, workflow efficiency, and customer growth strategies.
  • Deliver educational programs through in-person, virtual, and hybrid learning experiences that advance customer knowledge, skills, and confidence.
  • Help design and implement scalable education solutions that support adoption of the J&J Surgical Vision portfolio and evolving customer needs.
  • Facilitate learning experiences that enable customers to improve clinical and business outcomes.
  • Lead peer-to-peer educational initiatives among ophthalmologists, optometrists, practice administrators, technicians, and clinic staff.
  • Build and maintain relationships with key opinion leaders, faculty members, and industry experts to expand engagement and educational impact.
  • Support the identification and development of customer success stories and best practices for organizational use.
  • Partner with Marketing, Medical Affairs, Professional Education, Sales Training, and Corporate Accounts to develop customer-centric educational resources and tools.
  • Ensure educational content is aligned with business strategy, customer needs, and compliance requirements.
  • Collaborate across functions to drive consistency, quality, and effectiveness of education programs and customer engagements.
  • Support regional meetings, national sales meetings, industry congresses, professional education events, and customer programs as a subject matter expert.
  • Equip field teams with resources, tools, and insights that enhance customer conversations and business impact.
  • Partner with field leadership to drive successful execution and sustainability of educational initiatives.
  • Establish metrics and feedback mechanisms to evaluate program effectiveness, customer engagement, and business impact.
  • Analyze data and customer insights to identify opportunities for continuous improvement and innovation.
  • Share learnings and best practices to enhance organizational capabilities and customer outcomes.
  • Monitor marketplace trends, emerging technologies, and customer needs within ophthalmology and optometry.
  • Support new product introductions, market development activities, and innovation initiatives through education and customer engagement.
  • Identify opportunities to strengthen J&J Surgical Vision leadership through differentiated education and practice development solutions.
Desired Qualifications
  • Expertise in practice management, premium conversion strategies, and customer business optimization.
  • Experience supporting commercial organizations within medical device, vision care, or ophthalmology markets.
  • Faculty, speaker, training, or professional education experience.
  • Experience developing educational content, digital learning resources, and customer engagement programs.
  • Advanced ophthalmic certifications or additional clinical credentials.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.